Citadel Investment Advisory Inc. Has $1.53 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Citadel Investment Advisory Inc. lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 3,635 shares of the company’s stock after selling 25 shares during the period. IDEXX Laboratories makes up 0.7% of Citadel Investment Advisory Inc.’s portfolio, making the stock its 27th largest holding. Citadel Investment Advisory Inc.’s holdings in IDEXX Laboratories were worth $1,527,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hurley Capital LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth approximately $29,000. Rialto Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $30,000. Colonial Trust Co SC increased its stake in shares of IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after purchasing an additional 39 shares during the period. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $38,000. Finally, Itau Unibanco Holding S.A. lifted its holdings in IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock worth $40,000 after purchasing an additional 81 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Stifel Nicolaus upped their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a “hold” rating in a report on Monday, May 19th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, May 30th. Leerink Partners upped their price target on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an “outperform” rating in a research note on Wednesday, June 11th. Finally, Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research note on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $546.00.

Insider Activity

In related news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now directly owns 1,801 shares of the company’s stock, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $522.70 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $530.73. The firm has a market cap of $42.04 billion, a P/E ratio of 48.99, a price-to-earnings-growth ratio of 3.41 and a beta of 1.55. The business’s fifty day moving average is $473.11 and its 200-day moving average is $444.61.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. IDEXX Laboratories’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.71 earnings per share. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.